Becton Dickinson & Co.: Device Recall
Recall #Z-0621-2025 · 11/06/2024
Class II: Risk
Recall Details
- Recall Number
- Z-0621-2025
- Classification
- Class II
- Product Type
- Device
- Recalling Firm
- Becton Dickinson & Co.
- Status
- Ongoing
- Date Initiated
- 11/06/2024
- Location
- Sparks, MD, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,190 units
Reason for Recall
BD identified through potency testing as part of a stability test request to monitor Ampicillin AM-2 due to decrease in potency results of 65% at 18 months, may result in falsely resistant result for ampicillin susceptibility
Product Description
BD BBL Sensi Disc Ampicillin 2 ¿g (AM-2) - In-Vitro BD BBL Sensi Disc Ampicillin 2 ¿g (AM-2) are used for semi-quantitative in vitro susceptibility testing by the agar disc diffusion test procedure of common, rapidly growing and certain fastidious bacterial pathogens. Catalog Number: 231263
Distribution Pattern
Worldwide - US Nationwide distribution in the states of CA, GA, IL, KY, MA, MD, NE, PA and the countries of Canada, Belgium, Singapore, Malaysia.
Other Recalls by Becton Dickinson & Co.
- Class II: Risk 10/23/2025
- Class II: Risk 09/23/2025
- Class II: Risk 09/23/2025
- Class II: Risk 09/23/2025
- Class II: Risk 09/23/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.